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Abstract
Background: Interleukin 27 (IL-27) has pleiotropic properties that can either limit or enhance immune responses.
Recent studies revealed that single nucleotide polymorphisms (SNPs) of the IL-27 promoter region modulate the
development of infectious diseases and individual’s susceptibility to therapeutic response. Little is known about the
relationship between IL-27 single nucleotide polymorphisms and therapy response in patients infected by hepatitis
C virus (HCV). In this study we have investigated the potential role of SNPs in the promoter region of IL27 p28 gene
(alleles rs153109) on the outcome of HCV infected patients.
Methods: rs153109, corresponding to position c.-964A>G of the IL-27 locus, was amplified from genomic DNA
extracted from 15 patients with chronic hepatitis C stratified by sustained viral response (SVR), relapser and non-
responder, after treatment with peginterferon-a (PegIFN- a) combined with ribavirin (RBV). Amplification products
were studied by direct sequencing.
Results: This method has been applied in a preliminary study on patients with chronic hepatitis C to provide
information for a standardized assay useful to genotyping of rs153109 SNPs of IL-27p28. The genotype distribution
of the c.-964 A>G polymorphism was more present in patients who did not achieve a SVR. By contrast, the
genotype G/G was absent in non-responder and relapser patients. Moreover, the analysis of allelic distribution of
rs153109 highlighted a predominance of allele A in all genotypes in spite of allele G.
Conclusions: Our work provides preliminary information for a standardized method potentially useful for
genotyping rs153109, and suggests its utility as a candidate approach to evaluate IL-27 p28 polymorphisms as
additional clinical predictors of response to therapies in HCV infected patients.
Background
In agreement to the broad role that cytokines play in
shaping many aspects of innate and adaptive immunity,
there was a concerted effort toward identifying single
nucleotide polymorphisms (SNPs) of cytokine associated
with human diseases [1].
Interleukin 27 (IL-27) is a novel Interleukin 12 (IL-12)
family member, formed by the dimerization of two
subunits, Epstein-Barr virus-induced gene 3 (EBI3) and
IL-27p28, which engages a receptor composed of gp130
and IL-27Ra activating Janus kinase (JAK)/signal transdu-
cer and activator of transcription (STAT) and mitogen
activated protein kinase (MAPK) signaling. The human
IL-27 gene is located on chromosome 16p11 and consists
of five exons. Recently, both c.-964A/G ( rs153109) and
2905T/G (rs 181206) polymorphisms, corresponding to
promoter region of IL-27p28 gene, were identified to be
associated with individual susceptibility of asthma, inflam-
matory bowel diseases [2,3]. The findings of Huang et al.,
[4] suggest that polymorphisms of IL-27 gene -964 A/G
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may not be involved in susceptibility to colorectal cancer
(CRC), but this does not exclude the possible involvement
of other polymorphisms of IL-27 like 2905 T/G (rs
181206). Moreover, Robinson et al. [5] showed the ability
of IL-27 to regulate the macrophage activity during Myco-
bacterium tuberculosis infection while Peng et al., [6] asso-
ciated SNPs of IL-27 gene with the development of chronic
hepatitis B.
Furthermore, recent reports have shown that IL-27 sig-
nificantly induces interferon (IFN)-inducible antiviral
genes, suggesting that IL-27 inhibits human immunodefi-
ciency virus (HIV), influenza virus and hepatitis C virus
(HCV) replication by eliciting an IFN-like response [7-10].
The mechanisms underlying the HCV-induced liver
damage have not been completely clarified yet. Several stu-
dies have shown that hepatitis pathogenesis and the rate of
liver disease progression are influenced by several factors
such as environmental parameters and viral factors (geno-
type and level of viremia) [11-15].
However, this approach is considered limitative
because the evolution of liver disease and the response to
treatment appear to be the result of a dynamic process in
which genetic factors of host are mainly involved.
Indeed, information about genetic variants, either
mutant or polymorphic, represents the basis for the devel-
opment of new clinical approach for the management of
chronic HCV infected patients [16]. Several independent
genome-wide association studies (GWAS) have reported
that SNPs near the gene IL-28B are strongly correlated
with HCV containment, spontaneous clearance, host
response to antiviral treatment and disease progression
[17-19].
All these findings prompted us to hypothesize that
interleukin-27 could influence the HCV infection sus-
ceptibility and response to therapy.
In this report, we show the development of an assay
useful to detect SNP of the promoter region of IL27 p28
gene ( rs153109) and report preliminary data on HCV
RNA-positive patients undergoing treatment with pegin-
terferon-a (PegIFN- a) combined with ribavirin (RBV).
Methods
Patients
The study was designed as a retrospective analysis.
The sample of individuals studied was composed of
15 patients with chronic hepatitis C. All subjects were
treated with Peg-IFN-a-2a at a fixed dose of 180 μg/week
or with Peg-IFN-a-2b at 1.5 μgr/kg/week and ribavirin
800-1.200 mg/day (i.e., 800 mg for patients <65 kg; 1.000
mg for patients weighing 65 to 85 kg; 1.200 mg for
patients weighing 85 to 105 kg). Patients with HCV geno-
type 1 were treated for 24-48 weeks and 24 weeks in
patients with genotype non-1.
The sample was stratified according to therapeutic
response in: sustained viral response (HCV RNA nega-
tive 24 weeks after cessation of treatment, SVR), relapser
(reappearance of HCVRNA in serum after therapy is
discontinued) and non-responder (failure to decrease
HCV RNA < 2 log10 after 24 weeks of therapy). Baseline
characteristics of 15 patients with hepatitis C are sum-
marized in Table 1.
The study was approved by the Ethic Committee of
University Hospital Mater Domini, Catanzaro, Italy and
the patients signed an informed consent.
Extraction of genomic DNA, primers design, sequencing
analysis of SNP rs 153109
Genomic DNA was extracted from peripheral blood leu-
kocyte samples by a Genomic DNA Extraction kit
(Nuclear Laser Medicine S.r.l.), according to the manu-
facturer’s directions. DNA quality was assessed by calcu-
lating the absorbance ratio OD260nm/280nm using
NanoDrop (Thermo scientific 1000 spectrophotometer)
and by electrophoresis on 1% agarose gel.












Virogical Response to PEG-INF-a/RBV
SVR 5 (33.3)
Relapser 4 (26.7)











A Allele 14 (93.3)
Total 15
PegIFN-a, peginterferon-a; RBV, Ribavirin; SVR, Sustained Viral Response; APRI
SCORE, AST to Platelet Ratio Index;
Zicca et al. BMC Infectious Diseases 2014, 14(Suppl 5):S5
http://www.biomedcentral.com/1471-2334/14/S5/S5
Page 2 of 6
Primers were designed to amplify rs 153109; length of the
amplification product was 306bp. The primers used in this
study were the following: rs153109_F 5’-gTg TACAGCT-
gAACTCACAg-3’ and rs153109_R 5’-gCCTCTACAgAg-
CAgAAAC-3’ (see Figure 1).
Polymerase Chain Reaction (PCR) was performed in a
thermocycler VERTI 96well (Applied Biosystems) in a
total volume of 50 μl containing 150 ng genomic DNA,
25 μM primers, 1,25 U Taq DNA Polymerase, 50 m M
KCl, 30 m M Tris- Tris-HCl, 1,5 mM Mg2+ (MasterMix
2.5 x, 5prime) and 200 μM dNTP. PCR was carried out
under the following thermal cycler conditions: initial
denaturation at 95°C for 3 minutes, followed by 38
cycles consisting of denaturation at 95°C for 30 seconds,
annealing at 52° C for 30 seconds, extension at 72°C for
40 seconds; a final extension at 72°C for 5 minutes was
performed.
After purification using PCR Illustra MicroSpin S-300
Colonne HR (Gelifesciences UK), amplification products
were used as template DNA for sequencing analysis
(ABI Prism Big Dye Terminator Cycle Sequencing
Ready Reaction kit version 1.1 on an ABI PRISM 3100
genetic analyzer [Applied Biosystems]). PCR products
were studied by direct sequencing (see Figure 2).
SNP rs153109 were detected by sequence analysis
based on the reference sequence of Homo sapiens chro-
mosome 16 genomic contig GRCh37.p13 Primary
Assembly (NCBI Reference Sequence: NT_010393.16).
Results and future developments
In this preliminary report, we evaluated the rs153109
alleles of the IL27p28 gene in patients with chronic
hepatitis C using a direct sequencing approach. In parti-
cular, we analyzed the genotype of this SNP on c.
-964A>G. Our data show a different distribution of gen-
otype and allele of SNP in our patients. Indeed, the A/G
genotype is present in non-responders and relapser
compared to patients with a sustained viral response
(SVR). In addition, the G/G genotype was absent in
patients who negatively respond to antiviral therapy.
Moreover, the analysis of allele distributions of the
SNPs highlights a predominance of allele A in all geno-
types in spite of allele G (see Figure 3).
It is well known that host and viral factors can predict
treatment outcome; host factor, such as SNPs of Inter-
leukin 28A (IL28A), Interleukin 28B (IL28B), Interleukin
29 (IL 29), interferon-g (IFN- g), mannan binding lectin
(MBL), Interleukin 10 (IL−10), Interleukin 18 (IL-18),
human cytotoxic T-lymphocyte antigen 4 (CTLA 4),
Tumor necrosis factor-related apoptosis inducing ligand
receptor 1 (TRAIL), Transforming growth factor (TGF-
b), Osteopontin, low molecular mass polypeptides (LMP
7), oligoadenylate synthetase (OAS1) genes, insulin resis-
tance, obesity and ethnicity, have been found to modu-
late treatment response [20]. Moreover, there is still a
great effort for discovering new direct-acting inhibitors
of HCV that will be used in combination with interferon
or without it. For these reasons, further studies on host
genetic factors that may predict the treatment outcome
of combinational therapies and progression of liver dis-
ease are required.
IL-27 is one of the critical cytokines that functions as a
mediator between the innate and adaptive immune sys-
tem. Moreover, IL-27 synergizes with IL-12 to potentiate
Figure 1 The nucleotide sequence around rs153109 is shown. Sequences corresponding to forward and reverse primers to determine
rs153109 polymorphism are underlined.
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Figure 2 SNP rs153109 direct sequencing. Representative electropherogram of direct sequencing analysis, heterozygote A/G (A) and
homozygote A/A e G/G (B). The red rectangles indicate the SNP position.
Figure 3 Distribution of genotype of SNP rs153109 of IL-27p28 gene. The eterozygote genotype A/G of SNP is principally present in non-
responder and relapser patients compared to subjects with a sustained viral response (SVR). The homozygote genotype G/G was totally absent
in patients who respond negatively to antiviral therapy and the analysis of allele frequencies of the SNPs highlights a predominance of allele A
in all genotype in spite of allele G.
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Interferon-g (IFN-g) production by activated naïve T- and
Natural Killer (NK) cell populations [21]. Recent studies
revealed that SNPs of the IL-27 promoter region modu-
late the development of infectious diseases and indivi-
dual’s susceptibility to therapeutic response [5,6].
Our work provides information for a standardized
method useful to genotyping of rs153109 and might
suggest an association between treatment response and
genetic variability of IL-27p28 SNPs.
Given the small number of patients studied, the statis-
tical association demonstrated in this study may have
occurred by chance. However, this approach could
represent an interesting starting point for future investi-
gations. Therefore, a larger sample size should confirm
our results. Moreover, prospective studies should sup-
port the causal relationship between the presence of A/
G genotype in non-responder and relapser patients, as
well as the major presence of A allele. So, could allow
us to identify IL-27p28 SNPs as novel genetic markers
which may correlate with therapy response and, possi-
bly, with liver disease progression in HCV infected
patients.
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